An observational study in Diffuse Large B Cell Lymphoma, sponsored by MorphoSys AG. Completed at 57 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-24.
Sponsored by MorphoSys AG · Observational
This observational study is designed to characterise the effectiveness of lenalidomide monotherapy in the treatment of R/R DLBCL and to compare the results with the efficacy outcomes of a tafasitamab-lenalidomide combination therapy in the clinical trial MOR208C203 (L-MIND)
Tafasitamab (MOR00208) is currently in development for the treatment of R/R DLBCL. An ongoing, single-arm, phase II, open label, multicenter study (MOR208C203) is evaluating the efficacy and safety of tafasitamab combined with lenalidomide in patients with R/R DLBCL. In order to establish a lenalidomide monotherapy as a control cohort, this observational study aims to collect retrospective lenalidomide monotherapy data from real-world-evidence and to compare it with the tafasitamab-lenalidomide combination therapy.
5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.
This study's enrollment of 490 is above the median of 136 across 625 observational studies indexed under Lymphoma.
Browse Lymphoma studies →MorphoSys AG is the lead sponsor of 11 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
R/R DLBCL patients not eligible for HDC followed by ASCT who were treated with lenalidomide monotherapy
Exclusion Criteria:
Best overall/objective response rate (ORR)
Proportion of patients with complete response (CR) or partial response (PR) as best response achieved at any time during the study
Time frame: Through study completion, an average of 9 months
Overall survival
Time from treatment start until death from any cause
Time frame: Through study completion, an average of 9 months
Complete response rate
Proportion of patients having CR based on the best objective response achieved at any time during the study
Time frame: Through study completion, an average of 9 months
Disease control rate
Proportion of patients having CR, PR or stable disease (SD) based on the best objective response achieved at any time during the study
Time frame: Through study completion, an average of 9 months
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MorphoSys AG